{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:41:31Z","timestamp":1790638891379,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI 105980"],"award-info":[{"award-number":["AI 105980"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI 111753"],"award-info":[{"award-number":["AI 111753"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI 098724"],"award-info":[{"award-number":["AI 098724"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Microbiology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.mib.2016.05.017","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T01:15:45Z","timestamp":1467249345000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"special_numbering":"C","title":["Antisense antimicrobial therapeutics"],"prefix":"10.1016","volume":"33","author":[{"given":"Erin K","family":"Sully","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mib.2016.05.017_bib0445","first-page":"347","article-title":"Antisense oligonucleotides: basic concepts and mechanisms","volume":"1","author":"Dias","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.mib.2016.05.017_bib0450","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1016\/S0021-9258(18)47090-1","article-title":"Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding","volume":"269","author":"Brown","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mib.2016.05.017_bib0455","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nm1195-1116","article-title":"The state of the art in antisense research","volume":"1","author":"Wagner","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.mib.2016.05.017_bib0460","doi-asserted-by":"crossref","first-page":"14533","DOI":"10.1074\/jbc.271.24.14533","article-title":"Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras","volume":"271","author":"Monia","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mib.2016.05.017_bib0465","first-page":"288","article-title":"Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc\/CIBA vision","volume":"3","author":"Orr","year":"2001","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.mib.2016.05.017_bib0470","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.3390\/molecules16064511","article-title":"Locked and unlocked nucleosides in functional nucleic acids","volume":"16","author":"Doessing","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.mib.2016.05.017_bib0475","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1962210","article-title":"Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide","volume":"254","author":"Nielsen","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.mib.2016.05.017_bib0480","first-page":"89","article-title":"An introduction to peptide nucleic acid","volume":"1","author":"Nielsen","year":"1999","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.mib.2016.05.017_bib0485","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nbt0498-355","article-title":"Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA","volume":"16","author":"Good","year":"1998","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.mib.2016.05.017_bib0490","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/oli.1.1996.6.267","article-title":"Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation","volume":"6","author":"Hudziak","year":"1996","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/j.mib.2016.05.017_bib0495","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","article-title":"Morpholino antisense oligomers: design, preparation, and properties","volume":"7","author":"Summerton","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/j.mib.2016.05.017_bib0500","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0167-4781(99)00150-5","article-title":"Morpholino antisense oligomers: the case for an RNase H-independent structural type","volume":"1489","author":"Summerton","year":"1999","journal-title":"Biochim Biophys Acta (BBA) \u2013 Gene Struct Expr"},{"key":"10.1016\/j.mib.2016.05.017_bib0505","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1038\/srep10029","article-title":"Resveratrol antibacterial activity against Escherichia coli is mediated by Z-ring formation inhibition via suppression of FtsZ expression","volume":"5","author":"Hwang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.mib.2016.05.017_bib0510","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cell.2015.01.015","article-title":"EBV noncoding RNA binds nascent RNA to drive host PAX5 to viral DNA","volume":"160","author":"Lee","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.mib.2016.05.017_bib0515","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.micres.2013.12.008","article-title":"Functional analysis of mce4A gene of Mycobacterium tuberculosis H37Rv using antisense approach","volume":"169","author":"Chandolia","year":"2014","journal-title":"Microbiol Res"},{"key":"10.1016\/j.mib.2016.05.017_bib0520","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/9893","article-title":"Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A","volume":"17","author":"Mizuta","year":"1999","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.mib.2016.05.017_bib0525","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.00644-06","article-title":"Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers","volume":"50","author":"Ge","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2016.05.017_bib0530","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.virol.2005.08.034","article-title":"Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3\u2032 stem\u2013loop structure","volume":"344","author":"Holden","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.mib.2016.05.017_bib0535","doi-asserted-by":"crossref","first-page":"9665","DOI":"10.1128\/JVI.79.15.9665-9676.2005","article-title":"Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers","volume":"79","author":"Neuman","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.mib.2016.05.017_bib0540","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1128\/JVI.79.8.4599-4609.2005","article-title":"Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication","volume":"79","author":"Deas","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.mib.2016.05.017_bib0545","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1128\/AAC.37.9.1945","article-title":"Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region","volume":"37","author":"Azad","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2016.05.017_bib0550","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1081\/NCN-100002569","article-title":"Antisense oligonucleotide ISIS 2922 targets IE-expression and prevents HCMV-IE-induced suppression of TSP-1 and TSP-2 expression","volume":"20","author":"Margraf","year":"2001","journal-title":"Nucleos Nucl Nucleic Acids"},{"key":"10.1016\/j.mib.2016.05.017_sbref0555","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/AAC.04220-14","article-title":"In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122","volume":"59","author":"Ottosen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2016.05.017_bib0560","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1371\/journal.ppat.0020001","article-title":"Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers","volume":"2","author":"Warfield","year":"2006","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mib.2016.05.017_bib0565","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1099\/vir.0.80622-0","article-title":"Inhibition of Marburg virus protein expression and viral release by RNA interference","volume":"86","author":"Fowler","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.mib.2016.05.017_bib0570","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.2202","article-title":"Advanced antisense therapies for postexposure protection against lethal filovirus infections","volume":"16","author":"Warren","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.mib.2016.05.017_sbref0575","doi-asserted-by":"crossref","first-page":"e02344","DOI":"10.1128\/mBio.02344-14","article-title":"A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection","volume":"6","author":"Warren","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.mib.2016.05.017_bib0580","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1128\/AAC.00936-08","article-title":"Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection","volume":"53","author":"Swenson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2016.05.017_sbref0585","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa1410345","article-title":"AVI-7288 for marburg virus in nonhuman primates and humans","volume":"373","author":"Heald","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2016.05.017_bib0590","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(11)60281-X","article-title":"Chikungunya: a re-emerging virus","volume":"379","author":"Burt","year":"2012","journal-title":"The Lancet"},{"key":"10.1016\/j.mib.2016.05.017_bib0595","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.antiviral.2013.06.009","article-title":"Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy","volume":"99","author":"Thiberville","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.mib.2016.05.017_bib0600","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4269\/ajtmh.14-0442","article-title":"Chikungunya virus infections among travellers\u2014United States, 2010\u20132013","volume":"92","author":"Lindsey","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.mib.2016.05.017_bib0605","doi-asserted-by":"crossref","first-page":"12727","DOI":"10.1038\/srep12727","article-title":"Antiviral phosphorodiamidate morpholino oligomers are protective against Chikungunya virus infection on cell-based and murine models","volume":"5","author":"Lam","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.mib.2016.05.017_bib0610","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/cid\/ciu852","article-title":"Review of enterovirus 71 vaccines","volume":"60","author":"Chong","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2016.05.017_bib0615","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s00705-014-2054-y","article-title":"In vitro and in vivo protection against enterovirus 71 by an antisense phosphorothioate oligonucleotide","volume":"159","author":"Liu","year":"2014","journal-title":"Arch Virol"},{"key":"10.1016\/j.mib.2016.05.017_bib0620","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7150\/ijms.2.50","article-title":"Epidemiology and prevention of hepatitis B virus infection","volume":"2","author":"Hou","year":"2005","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.mib.2016.05.017_bib0625","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.mib.2016.05.017_bib0630","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1128\/CVI.05355-11","article-title":"Use of pre-S protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection","volume":"19","author":"Yum","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.mib.2016.05.017_bib0635","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0042-6822(89)90356-5","article-title":"Expression mechanism of the hepatitis B virus (HBV) C gene and biosynthesis of HBe antigen","volume":"170","author":"Jean-Jean","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.mib.2016.05.017_bib0640","doi-asserted-by":"crossref","first-page":"10087","DOI":"10.4238\/2015.August.21.16","article-title":"Antiviral effect of hepatitis B virus S\/C gene loci antisense locked nucleic acid on transgenic mice in vivo","volume":"14","author":"Deng","year":"2015","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.mib.2016.05.017_sbref0645","article-title":"In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides","author":"Billioud","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.mib.2016.05.017_bib0650","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1601-0825.2007.01419.x","article-title":"Hepatitis C: a clinical review","volume":"14","author":"Modi","year":"2008","journal-title":"Oral Dis"},{"key":"10.1016\/j.mib.2016.05.017_bib0655","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.mib.2016.05.017_bib0660","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.chom.2008.05.013","article-title":"Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome","volume":"4","author":"Jopling","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.mib.2016.05.017_bib0665","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/apt.13432","article-title":"Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma","volume":"43","author":"van der Ree","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mib.2016.05.017_bib0670","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14218\/JCTH.2014.00041","article-title":"Sofosbuvir, a significant paradigm change in HCV treatment","volume":"3","author":"McQuaid","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.mib.2016.05.017_bib0675","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nchembio837","article-title":"Drug discovery and development for neglected parasitic diseases","volume":"2","author":"Renslo","year":"2006","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.mib.2016.05.017_bib0680","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/85671","article-title":"Inhibition of gene expression in Entamoeba histolytica with antisense peptide nucleic acid oligomers","volume":"19","author":"Stock","year":"2001","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.mib.2016.05.017_bib0685","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpddr.2014.02.002","article-title":"Drug repurposing and human parasitic protozoan diseases","volume":"4","author":"Andrews","year":"2014","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.mib.2016.05.017_bib0690","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/CMR.00051-10","article-title":"Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination","volume":"24","author":"Bousema","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.mib.2016.05.017_bib0695","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature01097","article-title":"Genome sequence of the human malaria parasite Plasmodium falciparum","volume":"419","author":"Gardner","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.mib.2016.05.017_sbref0700","doi-asserted-by":"crossref","first-page":"e86802","DOI":"10.1371\/journal.pone.0086802","article-title":"Use of peptide nucleic acids to manipulate gene expression in the malaria parasite Plasmodium falciparum","volume":"9","author":"Kolevzon","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.mib.2016.05.017_bib0705","first-page":"3055","article-title":"PfSec13 is an unusual chromatin-associated nucleoporin of Plasmodium falciparum that is essential for parasite proliferation in human erythrocytes","volume":"126","author":"Dahan-Pasternak","year":"2013","journal-title":"J Cell Sci"},{"key":"10.1016\/j.mib.2016.05.017_bib0710","doi-asserted-by":"crossref","first-page":"11935","DOI":"10.1073\/pnas.1515864112","article-title":"Targeting protein translation, RNA splicing, and degradation by morpholino-based conjugates in Plasmodium falciparum","volume":"112","author":"Garg","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.mib.2016.05.017_bib0715","doi-asserted-by":"crossref","DOI":"10.2144\/000113005","article-title":"Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues","volume":"45","author":"Morcos","year":"2008","journal-title":"Biotechniques"},{"key":"10.1016\/j.mib.2016.05.017_bib0720","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1128\/CMR.00005-11","article-title":"Trypanosoma cruzi and Chagas\u2019 disease in the United States","volume":"24","author":"Bern","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.mib.2016.05.017_bib0725","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(10)60061-X","article-title":"Chagas disease","volume":"375","author":"Rassi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.mib.2016.05.017_bib0730","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4067\/S0716-97602010000300009","article-title":"Chagas disease: present status of pathogenic mechanisms and chemotherapy","volume":"43","author":"Maya","year":"2010","journal-title":"Biol Res"},{"key":"10.1016\/j.mib.2016.05.017_bib0735","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1038\/srep04231","article-title":"Antisense oligonucleotides targeting parasite inositol 1,4,5-trisphosphate receptor inhibits mammalian host cell invasion by Trypanosoma cruzi","volume":"4","author":"Hashimoto","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.mib.2016.05.017_bib0740","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/mmi.12155","article-title":"Inositol 1,4,5-trisphosphate receptor regulates replication, differentiation, infectivity and virulence of the parasitic protist Trypanosoma cruzi","volume":"87","author":"Hashimoto","year":"2013","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.mib.2016.05.017_bib0745","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.parint.2015.12.001","article-title":"Morpholino antisense oligo inhibits trans-splicing of pre-inositol 1,4,5-trisphosphate receptor mRNA of Trypanosoma cruzi and suppresses parasite growth and infectivity","volume":"65","author":"Hashimoto","year":"2016","journal-title":"Parasitol Int"},{"key":"10.1016\/j.mib.2016.05.017_bib0750","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","article-title":"Toxoplasma gondii: from animals to humans","volume":"30","author":"Tenter","year":"2000","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.mib.2016.05.017_bib0755","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.parint.2014.05.001","article-title":"Silencing of GRA10 protein expression inhibits Toxoplasma gondii intracellular growth and development","volume":"63","author":"Witola","year":"2014","journal-title":"Parasitol Int"},{"key":"10.1016\/j.mib.2016.05.017_bib0760","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of beta-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.mib.2016.05.017_bib0765","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1073\/pnas.78.3.1537","article-title":"Selective inhibition of Escherichia coli protein synthesis and growth by nonionic oligonucleotides complementary to the 3\u2032 end of 16S rRNA","volume":"78","author":"Jayaraman","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.mib.2016.05.017_bib0770","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/86753","article-title":"Bactericidal antisense effects of peptide\u2013PNA conjugates","volume":"19","author":"Good","year":"2001","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.mib.2016.05.017_bib0775","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1073\/pnas.1306911110","article-title":"Combined effect of a peptide\u2013morpholino oligonucleotide conjugate and a cell-penetrating peptide as an antibiotic","volume":"110","author":"Wesolowski","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.mib.2016.05.017_bib0780","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0167-4781(98)00126-2","article-title":"DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities","volume":"1400","author":"Levine","year":"1998","journal-title":"Biochim Biophys Acta (BBA) \u2013 Gene Struct Expr"},{"key":"10.1016\/j.mib.2016.05.017_bib0785","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1128\/AAC.42.10.2661","article-title":"gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae","volume":"42","author":"Weigel","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2016.05.017_bib0790","first-page":"2","article-title":"Inhibition of growth and gene expression by PNA\u2013peptide conjugates in Streptococcus pyogenes","author":"Patenge","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.mib.2016.05.017_bib0795","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1358\/dnp.2010.23.5.1429489","article-title":"FtsZ inhibition: a promising approach for antistaphylococcal therapy","volume":"23","author":"Singh","year":"2010","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.mib.2016.05.017_bib0800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2014.09.015","article-title":"Inhibiting the growth of methicillin-resistant Staphylococcus aureus in vitro with antisense peptide nucleic acid conjugates targeting the ftsZ gene","volume":"30","author":"Liang","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.mib.2016.05.017_bib0805","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1128\/AAC.00099-09","article-title":"Inhibition of intracellular growth of Salmonella enterica serovar Typhimurium in tissue culture by antisense peptide-phosphorodiamidate morpholino oligomer","volume":"53","author":"Mitev","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2016.05.017_bib0810","doi-asserted-by":"crossref","first-page":"20832","DOI":"10.1038\/srep20832","article-title":"Impact of different cell penetrating peptides on the efficacy of antisense therapeutics for targeting intracellular pathogens","volume":"6","author":"Abushahba","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.mib.2016.05.017_bib0815","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/AAC.00917-08","article-title":"Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo","volume":"53","author":"Mellbye","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2016.05.017_bib0820","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijantimicag.2012.11.017","article-title":"Peptide nucleic acids inhibit growth of Brucella suis in pure culture and in infected murine macrophages","volume":"41","author":"Rajasekaran","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mib.2016.05.017_bib0825","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/jac\/dki129","article-title":"Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis","volume":"55","author":"Geller","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2016.05.017_sbref0830","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ijpharm.2013.05.041","article-title":"A peptide-morpholino oligomer conjugate targeting Staphylococcus aureus gyrA mRNA improves healing in an infected mouse cutaneous wound model","volume":"453","author":"Sawyer","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.mib.2016.05.017_bib0835","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1128\/AAC.03781-14","article-title":"Antisense growth inhibition of methicillin-resistant Staphylococcus aureus by locked nucleic acid conjugated with cell-penetrating peptide as a novel FtsZ inhibitor","volume":"59","author":"Meng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2016.05.017_sbref0840","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jit460","article-title":"Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo","author":"Geller","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.mib.2016.05.017_bib0845","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrd3013","article-title":"Anti-virulence strategies to combat bacteria-mediated disease","volume":"9","author":"Rasko","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.mib.2016.05.017_bib0850","series-title":"ASM Microbe","article-title":"Inhibition of biofilm and quorum-sensing pathways in Pseudomonas aeruginosa by peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs). Poster","author":"Sturge","year":"2016"},{"key":"10.1016\/j.mib.2016.05.017_bib0855","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/jac\/dkl412","article-title":"Role of the CmeABC efflux pump in the emergence of fluoroquinolone-resistant Campylobacter under selection pressure","volume":"58","author":"Yan","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2016.05.017_bib0860","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/jac\/dkt381","article-title":"Target optimization for peptide nucleic acid (PNA)-mediated antisense inhibition of the CmeABC multidrug efflux pump in Campylobacter jejuni","volume":"69","author":"Oh","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2016.05.017_bib0865","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12866-015-0599-x","article-title":"Oxacillin sensitization of methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus pseudintermedius by antisense peptide nucleic acids in vitro","volume":"15","author":"Goh","year":"2015","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.mib.2016.05.017_sbref0870","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/ja.2014.132","article-title":"Reversion of antibiotic resistance by inhibiting mecA in clinical methicillin-resistant Staphylococci by antisense phosphorothioate oligonucleotide","volume":"68","author":"Meng","year":"2015","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.mib.2016.05.017_bib0875","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/AAC.01304-15","article-title":"Inhibition of AAC(6\u2032)-Ib-mediated resistance to amikacin in Acinetobacter baumannii by an antisense peptide-conjugated 2\u2032,4\u2032-bridged nucleic acid\u2013NC\u2013DNA hybrid oligomer","volume":"59","author":"Lopez","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2016.05.017_bib0880","series-title":"ICAAC\/ICC","article-title":"NDM-1 positive Escherichia coli restored to carbapenem susceptibility in vivo by a peptide phosphorodiamidate morpholino oligomer. Poster","author":"Sully","year":"2015"}],"container-title":["Current Opinion in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527416300807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527416300807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:46:50Z","timestamp":1761284810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1369527416300807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":88,"alternative-id":["S1369527416300807"],"URL":"https:\/\/doi.org\/10.1016\/j.mib.2016.05.017","relation":{},"ISSN":["1369-5274"],"issn-type":[{"value":"1369-5274","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense antimicrobial therapeutics","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mib.2016.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}